key: cord-0775254-f7yz7rdn
authors: Cattaneo, Dario; Corbellino, Mario; Cozzi, Valeria; Fusi, Marta; Gervasoni, Cristina
title: Comment on “Comparative Population Pharmacokinetics of Darunavir in SARS-CoV-2 Patients vs. HIV Patients: The Role of Interleukin-6”
date: 2021-04-17
journal: Clin Pharmacokinet
DOI: 10.1007/s40262-021-00992-5
sha: 5e162df12dc69650dcab1d4e6521266a3d259c8d
doc_id: 775254
cord_uid: f7yz7rdn

nan

We read with interest the manuscript by Cojutti et al. [1] , which documented that darunavir clearance and drug trough concentrations were, respectively, 60% lower and five-fold higher in patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) compared with patients with human immunodeficiency virus (HIV) for the same daily drug dose (800 mg once daily). These results are in agreement with previous findings showing four-fold higher lopinavir trough concentrations in patients with SARS-CoV-2 vs patients with HIV [2] [3] [4] . As both HIV protease inhibitors are substrates of cytochrome P450 3A4, the authors hypothesized that the reduced clearance of darunavir and lopinavir in patients with SARS-CoV-2 could have been driven by an impairment of drug metabolism related to the viral infection. Remarkably, interleukin-6 was the only clinical covariate that significantly correlated with darunavir pharmacokinetics. Accordingly, it has been proposed that the acute viral infection perpetrated a pro-inflammatory state that may, in turn, downregulate cytochrome P450 3A4 expression and activity, ultimately resulting in increased darunavir systemic concentrations [1, 5] . As indirect support for this hypothesis, the authors have shown that lower interleukin-6 levels measured in the comparator group of patients with HIV were associated with higher darunavir clearance compared with patients with SARS-CoV-2.

Taken together, findings from lopinavir and darunavir can be considered as a proof of concept of viral disease-drug interactions, recalling the issue of optimal dose selection of the cytochrome P450 3A4 substrate in patients with SARS-CoV-2. We believe, however, that the study by Cojutti et al. lacks a third mandatory comparator group: the patients co-infected with HIV and SARS-CoV-2. The inclusion of this additional group could allow the characterization of the pharmacokinetics of darunavir in patients with the concomitant presence of chronic and acute inflammatory states related to chronic and acute viral infections, respectively.

To address this issue, we searched through the database of our Clinic of Infectious Diseases for HIV-infected patients with a diagnosis of SARS-CoV-2 infection, given darunavir as maintenance antiretroviral therapy who underwent therapeutic drug monitoring of darunavir trough concentrations during COVID-19. Data on interleukin-6 and/or C-reactive protein were also collected as biomarkers of acute inflammatory progression in patients with SARS-CoV-2. To indirectly verify the comparability of the darunavir trough concentrations in patients with SARS-CoV-2 described by Cojutti et al., with those measured in our patients coinfected with HIV/SARS-CoV-2, we also considered a control group of patients with HIV not infected with SARS-CoV-2 undergoing therapeutic drug monitoring of darunavir trough concentrations (as done by Cojutti et al. [1] ). Data were expressed as median (interquartile range); significance was set at p < 0.05.

Six patients with HIV co-infected with SARS-CoV-2 and fulfilling the inclusion criteria were retrieved from the database of our clinic. They were mostly male (four out of six), with a median age of 62 (58-64) years. As shown in Table 1 We could not make formal statistical comparisons between our datasets and the those from Cojutti et al. (individual darunavir concentrations for the latest study were not available). However, to a visual evaluation, the darunavir trough concentrations measured in patients co-infected with HIV/ SARS-CoV-2 and patients mono-infected with HIV from our cohort fully matched to those measured in the comparator group of patients with HIV from the other study (1010 [550-2112] ng/mL), resulting in five-fold lower than darunavir trough concentrations measured in patients monoinfected with SARS-CoV-2 (4960 [2015-7951] ng/mL). No major differences in the inflammatory states were observed between the two cohorts of patients with SARS-CoV-2 (Table 1) . Taken together, these findings provide indirect evidence that the observed differences in the darunavir trough concentrations between patients mono-infected with SARS-CoV-2 and patients co-infected with HIV/SARS-CoV-2 were not biased by potential analytical issues (the concentrations of darunavir in patients mono-infected with HIV measured in the two studies were comparable) or affected by key differences in the inflammatory status between the two cohorts (patients co-infected with HIV/SARS-CoV-2 and patients mono-infected with SARS-CoV-2 had comparable interleukin-6 levels). Moreover, the darunavir trough concentrations measured in patients mono-infected with HIV and patients co-infected with HIV/SARS-CoV-2 were similar to those measured previously in healthy volunteers given darunavir at 800 mg at steady state [6, 7] . Hence, combined evidence from our study and the Cojutti et al. study provides two key messages: (a) the increased darunavir exposure can be attributed exclusively to SARS-CoV-2 and (b) this effect is switched off by the presence of concomitant HIV infection.

The mechanism by which HIV is able to mitigate the effects of SARS-CoV-2 on cytochromial enzyme activity and darunavir clearance cannot be derived from the present study given its retrospective naturalistic design. Despite these limitations, we believe that our case series, although small, may add another important piece to the puzzle well described by Cojutti et al. [1] , showing that in patients with SARS-CoV-2 co-infected with HIV the presence of a pro-inflammatory state does not result in increased darunavir exposure. Even though the clinical relevance of these findings remains to be explored, this is a good example of how the co-existence of acute and chronic inflammatory conditions might provide unexpected and unpredictable results on drug disposition. 

Comparative population pharmacokinetics of darunavir in SARS-CoV-2 patients vs. HIV patients: the role of interleukin-6

Lopinavir pharmacokinetics in COVID-19 patients

Pharmacokinetics of lopinavir and ritonavir in patients hospitalized with Coronavirus Disease 2019 (COVID-19)

Lopinavir/ritonavir in COVID-19 patients: maybe yes, but at what dose?

Impact of infectious and inflammatory disease on cytochrome P450-mediated drug metabolism and pharmacokinetics

Steady-state pharmacokinetics of darunavir/ritonavir and pitavastatin when co-administered to healthy adult volunteers

Pharmacokinetics of darunavir in fixed-dose combination with cobicistat compared with coadministration of darunavir and ritonavir as single agents in healthy volunteers